Esperion's hypercholesterolemia candidate meets in Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily 180 mg oral bempedoic acid (ETC-1002) met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo (23% vs. 1%, p<0.001) in the Phase III CLEAR Serenity (1002-046) trial to treat hypercholesterolemia in high-risk, statin-intolerant patients with atherosclerotic cardiovascular disease (ASCVD) or who were at high risk for ASCVD.

Bempedoic acid also met the secondary endpoints of reducing LDL-C from baseline to week 24 (26% vs. 2%, p<0.001) and of reducing high-sensitivity C-reactive protein (hsCRP) levels from baseline to week 12 (reduction of 25% vs. an increase of 3%, p<0.001) vs. placebo...